Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

Growing evidence indicates antibody-dependent cellular cytotoxicity (ADCC) contributes to the clinical response to monoclonal antibody (mAb) therapy of lymphoma. Recent in vitro analysis suggests C3b can inhibit mAb-induced natural killer (NK)–cell activation and ADCC. Further studies were conducted...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Wang, Siao-Yi, Veeramani, Suresh, Racila, Emilian, Cagley, Jeffrey, Fritzinger, David C., Vogel, Carl-Wilhelm, St John, William, Weiner, George J.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Hematology 2009
Θέματα:
Lymphoid Neoplasia
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2796137/
https://ncbi.nlm.nih.gov/pubmed/19805620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-01-200469
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια